Sidoti Csr Analysts Reduce Earnings Estimates for USNA

USANA Health Sciences, Inc. (NYSE:USNA) – Sidoti Csr dropped their Q1 2025 earnings per share (EPS) estimates for USANA Health Sciences in a research report issued to clients and investors on Wednesday, February 26th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings per share of $0.71 for the quarter, down from their previous estimate of $0.77. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q2 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.71 EPS, FY2025 earnings at $2.75 EPS, Q2 2026 earnings at $0.81 EPS and Q4 2026 earnings at $0.92 EPS.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. The company had revenue of $213.61 million during the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%.

Other research analysts have also issued research reports about the stock. Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Finally, DA Davidson lifted their target price on shares of USANA Health Sciences from $35.00 to $38.00 and gave the stock a “neutral” rating in a report on Thursday, January 2nd.

USANA Health Sciences Stock Performance

Shares of USNA opened at $33.17 on Thursday. The firm has a market cap of $632.26 million, a PE ratio of 11.72, a PEG ratio of 0.93 and a beta of 0.87. The firm’s 50 day moving average price is $33.62 and its 200 day moving average price is $36.61. USANA Health Sciences has a twelve month low of $30.13 and a twelve month high of $50.32.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds have recently modified their holdings of the stock. R Squared Ltd acquired a new stake in USANA Health Sciences in the 4th quarter valued at $28,000. Safe Harbor Fiduciary LLC bought a new position in shares of USANA Health Sciences during the third quarter valued at $30,000. KBC Group NV boosted its stake in shares of USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after purchasing an additional 519 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of USANA Health Sciences in the 4th quarter worth about $83,000. Finally, Quantbot Technologies LP bought a new stake in shares of USANA Health Sciences in the 4th quarter worth about $132,000. 54.25% of the stock is owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.